A Phase 1/2 interventional study of Etentamig and Isatuximab in Myeloma Multiple and Myeloma, sponsored by Universitätsklinikum Hamburg-Eppendorf. Not yet recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-20.
Sponsored by Universitätsklinikum Hamburg-Eppendorf · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing etentamig in Multiple Myeloma — 6 open to participants now, 10 under way, 3 of them phase 3. etentamig · Multiple Myeloma.
Among the 10 studies testing etentamig in Multiple Myeloma, this one is the 6th largest by planned enrollment, is one of 3 that started in 2026, is one of 3 in phase 1/2, and was the 9th registered.
3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
Browse Multiple Myeloma studies →6 of the 10 studies testing etentamig in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Israel, Japan and 1 more country
Ages 18+
AbbVie · Sites in United States, France, Japan and 1 more country
Ages 18+
AbbVie · Sites in United States, Australia, Canada and 4 more countries
Ages 18+
AbbVie · Sites in United States, Australia, Israel and 3 more countries
Ages 18+
AbbVie · Sites in United States, Canada, Denmark and 4 more countries
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 4 · Phase 3 3
First in 2019; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 220 is above the median of 41 across 3,009 interventional studies indexed under Multiple Myeloma.
Median enrollment 235 across the 10 interventional studies. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 2 most frequent:
Universitätsklinikum Hamburg-Eppendorf is the lead sponsor of 416 studies on the registry; 86 are open to participants now.
11 studies in Multiple Myeloma by Universitätsklinikum Hamburg-Eppendorf: 3 open now, 4 under way, none of them phase 3. Of 7 finished, 0 (0%) have results posted.
Among the 11 studies in Multiple Myeloma by Universitätsklinikum Hamburg-Eppendorf, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2026, is one of 3 in phase 1/2, and was the 10th registered.
Universitätsklinikum Hamburg-Eppendorf’s Multiple Myeloma studies by the year they started, since 2000.
1 of the studies testing etentamig in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06223516AbbVieStudy of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing etentamig in Multiple Myeloma, from their registry updates:
Among Universitätsklinikum Hamburg-Eppendorf’s 11 in Multiple Myeloma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is researching an experimental five-drug combination called etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) and high-risk disease who are eligible for autologous stem cell transplantation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
First dose level of etentamig to be explored in combination with Isa-VRd
Drug: Etentamig · Drug: Isatuximab · Drug: Bortezomib + Lenalidomide + Dexamethasone
Second dose level of etentamig to be explored in combination with Isa-VRd
Drug: Etentamig · Drug: Isatuximab · Drug: Bortezomib + Lenalidomide + Dexamethasone
RP2D of etentamig to be explored in combination with Isa-VRd
Drug: Etentamig · Drug: Isatuximab · Drug: Bortezomib + Lenalidomide + Dexamethasone
Administered per the protocol
Administered per the protocol
Drug pages: BortezomibStudies of BortezomibBortezomib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LenalidomideStudies of LenalidomideLenalidomide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · DexamethasoneStudies of DexamethasoneDexamethasone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Administered per the protocol
Safety and tolerability (Phase I)
Number of dose-limiting toxicities (DLTs) in participants and rates of adverse events (AEs) of grade ≥2 and of severe AEs in participants
Time frame: through induction treatment, on average 4 months
MRD negativity (Phase II)
MRD-negativity rate after 12 cycles (with a sensitivity of \<10-5)
Time frame: through consolidation phase completion, an average of 1 year
PFS
Progression-free survival
Time frame: up to 10 years
ORR
Overall response rate
Time frame: up to 10 years
CR rate
Complete Response Rate
Time frame: up to 10 years
VGPR Rate
Very good partial response rate
Time frame: up to 10 years
DoR
Duration of Response
Time frame: up to 10 years
TTR
Time to response
Time frame: up to 10 years
PFS2
Progression free survival 2
Time frame: up to 10 years
OS
Overall survival
Time frame: up to 10 years
MRD negativity
Minimal Residual Disease (MRD) Negativity Rate (10-5 to 10-6)
Time frame: up to 10 years
Sustained MRD
Sustained MRD negativity rate (for a duration of 6-months, and multiples therof)
Time frame: up to 10 years
MRD-negative CR
Rates of MRD-negative Complete Responses
Time frame: up to 10 years
Sustained MRD-negative CR
Rate of Sustained MRD-negative Complete Response
Time frame: up to 10 years
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Sep 2036, 117 months later.
Of 103 non-industry phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 94. This study's planned 117 months is above that.
Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etentamig
Universitätsklinikum Hamburg-Eppendorf →